Proteon Therapeutics Inc (NDAQ:PRTO) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Friday. They presently have a $3.00 price target on the stock.

Proteon Therapeutics (NDAQ:PRTO) traded down 6.06% on Friday, hitting $1.55. The stock had a trading volume of 18,496 shares. Proteon Therapeutics has a 52-week low of $1.40 and a 52-week high of $11.63. The stock’s 50-day moving average is $1.87 and its 200-day moving average is $5.83. The company’s market cap is $25.72 million.

Your IP Address:

About Proteon Therapeutics

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with's FREE daily email newsletter.